GSK reported third-quarter sales of £8.887 billion, up 5% at constant exchange rates, and reaffirmed its 2026 targets as sales rose across its specialty medicines businesses.
Sales increased 4% using actual exchange rates. Core EPS was 54.6 pence.
By business, Oncology generated £600 million, with sales up 23%; Respiratory, Immunology & Inflammation reached £1.1 billion, a 21% rise; HIV totaled £2.1 billion, up 10%; and Specialty Medicines brought in £3.9 billion, up 15%. All four growth rates are at constant exchange rates.
For 2026, GSK’s targets remain turnover growth of 3% to 5%. Core operating profit and Core EPS are each projected to rise 7% to 9% at constant exchange rates.
